PRIMARY PREVENTION OF VERRUCA PLANTARIS THROUGH TOPICAL HERBAL AND VITAMIN DERIVATIVE by DO ACOFP, MARK KEVIN KAUFFMAN et al.
International Journal of Applied Pharmaceutics
ISSN - 0975 - 7058 Vol 13, Special Issue 1, 2021
PRIMARY PREVENTION OF VERRUCA PLANTARIS THROUGH TOPICAL HERBAL AND VITAMIN 
DERIVATIVE
MARK KEVIN KAUFFMAN DO, FACOFP1, MICHELE MARIE ROTH-KAUFFMAN JD2, PRATEEK KHURANA1, 
LORRIE SINIBALDI1, AARON WALKOWSKI1, ANDREW APUGLIESE1, JUNAID ESSA1
1Department of Primary Care, Lake Erie College of Osteopathic Medicine, Bradenton, Florida. 2Department of Physician, Gannon 
University, Ruskin, Florida. Email: mkauffman@lecom.edu
Received: 04 November 2019, Revised and Accepted: 19 March 2020
ABSTRACT
Objective: Verrucae plantaris (VP) results from environmental exposure to human papillomavirus causing plantar warts of the foot, resistant 
to treatment, and high recurrence rates. Current treatment paradigms focus on the treatment of lesions as opposed to primary prophylaxis. We 
hypothesize that a topical combination of herbal supplement with anti-viral properties and a vitamin derivative* can be used prophylactically to 
decrease the primary incidence.
Methods: We initiated a double-blinded clinical study with participants (n=282) randomization into control (lotion emollient only) (n=120), 
treatment (herbal and vitamin derivative) (n=110) and no treatment (NT) (n=52). Participants underwent examination of the feet at baseline (0 
months) to exclude VP lesions and were randomized to receive a bottle containing topical lotion with emollient only, control (C), lotion with an herbal 
and vitamin derivative, treatment (T), or NT, where participants did not apply anything to their feet. C and T participants applied lotion topically to the 
feet once daily and were examined at 3, 6, 9, and 12 months to document the incidence of VP.
Results: No incidence of VP occurred in the T group (0/110=0% incidence), two lesions in the C group (2/120=1.7% incidence), and five lesions in 
the NT group (5/52=9.6% incidence).
Conclusion: Treatments for VP rely on treating lesions after they occur, have high degrees of variability in success, risk of continued transmission 
during treatment, and have high rates of recurrence. Although the study number is relatively low, early indications show decreasing incidence of 
VP from 9.6% in participants with NT to 1.7% in participants who used lotion only, suggesting increased health of the plantar epidermis, and 0% 
incidence in those participants applying topical herbal and vitamin derivative*. Additional study with increased numbers of participants is warranted.
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INTRODUCTION
Verrucae plantaris (VP), commonly known as plantar warts, is the 
result of environmental exposure to human papillomavirus (HPV) 
resulting in lesions on the plantar aspect of the foot [1-5] with an annual 
incidence of 14% [6] in the United States. Patients complain of esthetic 
embarrassment and pain or pressure sensation with activities increasing 
pressure on the foot [7-9] and fear of transmitting the infection [8].
VP is spread through desquamated epithelial cells to new hosts most 
commonly through the disruption of plantar epithelium [10]. Current 
treatment paradigms focus on the treatment of lesions once acquired, 
as opposed to primary prophylaxis, with variable success as deep 
penetration into the dermis makes lesions resistant to treatment and 
high recurrence rates [9,11]. Most treatment focuses on the destruction 
of the lesion rather than HPV itself [12]. To date, preventative 
measures focus on behavioral modification limiting primary exposure 
to HPV, such as avoiding bare feet in areas of high contamination. We 
hypothesize that a topical combination of herbal supplement with anti-
viral properties and vitamin derivative* can be used prophylactically to 
decrease primary incidence in high-risk populations.
Etiology
VP is caused by HPV, a group of non-enveloped DNA viruses. Twelve HPV 
types have been identified in VP lesions; HPV-1, -2, -3, -4, -27, -29, -57, -60, 
-63, -65, -66, and -69 [2,4,8,9]; however, most are attributed to HPV-1 with 
-2, -27, and -57 also having higher incidence [11]. Host infection occurs 
through direct contact with a wart shedding viral particles or indirectly 
through fomites found on floor surfaces or in footwear [4-9] which can 
survive for years outside the host [5]. Disrupted plantar epithelium 
provides a nidus for implantation of HPV [4,7] into the basal epithelial 
layer [13]. Viral DNA is then established within the host cell after an 
incubation period of 1–20 months [4]. The infected cells may then be 
cleared, become latent, or manifested as VP [6]. With manifestation, basal 
keratinocytes replicate resulting in hyper keratinized papules which 
release infectious viral particles from desquamated cells to infect other 
sites or hosts [10]. Due to pressure on the lesion, deeper penetration 
occurs, contributing to their resistance to therapy [1,7,8]. Spontaneous 
regression occurs in 65–78% in children within 2 years [6,11]; however, 
the rate significantly decreases [12] after the age of 12. 
Epidemiology
It is estimated that 40% of the US population is infected with HPV [4], 
with an annual incidence of VP of 14% in the general population [6]. 
Increase risk factors include increased exposure to HPV, epidermal barrier 
disruption, and inappropriate immune responses. Two percent of the adult 
population and 6% of the pediatric population seek care for a plantar wart 
annually [11]. VP is rare in patients under 5 years of age [5,8], occurring 
most frequently in children with a peak incidence between 12 and 16 
years of age [4]. Lesions in adults are more resistant to treatment [14].  
Children of higher educational and income, two-parent households, who 
have family members or close contacts with VP, or have preexistent VP are 
at increased risk [4,5,7,8]. Other at-risk groups include communal shower 
users, athletes, dancers, those who are immunocompromised [6].
Treatment 
Treatment options for VP include observation for self-resolution in 
immunocompetent patients, salicylic acid applied topically [9], and 
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cryotherapy with liquid nitrogen which has been shown to be less 
effective than salicylic acid [11] and may be associated with mobility-
limiting pain [15] and is not recommended for small children. Both 
may require weeks to months of daily applications and paring of the 
hyperkeratotic tissues [3,4,8]. With poor treatment outcomes and high 
rates of recurrence, primary prevention of VP by use of topical anti-
viral prophylaxis in high-risk populations coupled with diminishing 
risk factors and maintenance of the integrity of the epidermal barrier 
would represent a shift in treatment paradigm moving from the current 
standard of treating after the occurrence which is often costly and 
ineffective
METHODS
We initiated a double-blinded clinical research study consisting of 
two arms: Control (lotion emollient only) and treatment (herbal and 
vitamin derivative). The study Group I (SGI) consisted primarily of 
university age (18–24 years) participants with an attempt to recruit 
participants with high-risk activities such as participation in sports 
and communal recreational facility use. Participants underwent 
an examination of the feet at baseline (0 months) to document the 
presence of active lesions. Of the 161 participants, 5 had active VP 
with 5 participants being excluded due to primary VP at enrollment 
resulting in SGI (n=156). Participants were randomized into one of the 
two study arms; Green Bottle and Blue Bottle. One bottle contained 
topical lotion with emollient only control (C) (n=82) and the other a 
lotion with an herbal and vitamin derivative combination treatment 
(T) (n=74). Participants applied the lotions topically to the feet on a 
once-daily through metered-dose pumping. Participants were then 
examined at 3, 6, 9, and 12 months to document the incidence of VP 
occurrence. 
RESULTS
At the conclusion of the 12-month study, no incidence of VP occurred 
in either the control or treatment groups. Although this study group is 
relatively small (n=156), 80 (49.7%) participants self-identified with 
high-risk activities such as locker room use without shoes, swimming, 
karate, and yoga. With an estimated 14% annual incidence, some 
incidence of new lesions would be expected [6]. No incidence of new-
onset VP in either treatment group suggests that lotion alone may 
decrease the incidence of VP, likely due to increased integrity of the 
epidermis. This identified the lack of a study arm with no lotion for 
comparison. A second study group enrolled 131 participants, of which 
five were again excluded due to VP at enrollment resulting in study 
group 2 (SG2) with (n=126). This double-blinded study randomized 
participants into three study arms: No treatment (NT) (n=52), control 
(C) (n=38) – lotion emollient only, and treatment (T) (n=36) – herbal 
and vitamin derivative. NT participants do not apply anything to their 
feet. At study conclusion, there was no incidence of VP in the T group 
(0/36=0%), two in the C group (2/38=5.3%), and five in the NT group 
(5/52=9.6%).
Combined data from SG1 and SG2 (n=282) demonstrate no incidence of 
VP in the T group, herbal and vitamin derivative (0/110=0% incidence), 
two VP lesions in the C group, emollient only (2/120=1.7% incidence) 
group, and five VP lesions in the NT group, NT (5/52 = 9.6% incidence) 
Fig. 1.
CONCLUSION
Treatments for Verruca Plantaris have high degrees of variability in 
success requiring lengthy duration of treatment, risk of continued 
transmission during treatment, and high rate of recurrence. Current 
treatment relies on treating lesions after they occur. Although the 
study number is relatively low (n=282), early indications show 
decreasing incidence of VP from 9.6% in participants with NT to 1.7% 
in participants who used lotion only, suggesting increased health of the 
plantar epidermis, and 0% incidence in those participants applying 
topical herbal and vitamin derivative*.
*The herbal and vitamin derivatives used in this study constitute 
proprietary information. 
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Fig. 1: Incidence of Verruca Plantaris per treatment group
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